4125-97-7

Basic information

• Product Name: Z-MEILE-OH
• Synonyms: Benzyloxycarbonyl-N-methyl-L-isoleucine;NALPHA-Benzyloxycarbonyl-N-methyl-L-isoleucine;Isoleucine, N-benzyl-N-methyl-, L-;(2S,3S)-2-(Benzyl(methyl)amino)-3-methylpentanoic acid;-2-(Benzyl(methyl);BENZYLOXYCARBONYL-N-ALPHA-METHYL-L-ISOLEUCINE;BENZLOXYCARBONYL-N-METHYL-L-ISOLEUCINE;N-ALPHA-CARBOBENZOXY-N-ALPHA-METHYL-L-ISOLEUCINE
• CAS NO: 4125-97-7
• Molecular Formula: C₁₄H₂₁NO₂
• Molecular Weight: 279.33
• Product Categories: N-Methyl Amino Acids
• Mol File: 4125-97-7.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 419.449 °C at 760 mmHg
• Flash Point: 207.475 °C
• Appearance: /
• Density: 1.145g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Z-MEILE-OH(CAS DataBase Reference)
• NIST Chemistry Reference: Z-MEILE-OH(4125-97-7)
• EPA Substance Registry System: Z-MEILE-OH(4125-97-7)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 4125-97-7(Hazardous Substances Data)

Usage

General Description

Z-MEILE-OH, also known as 2-(2-methoxyethoxy)ethanol, is a chemical compound with the molecular formula C5H12O3. It is a clear, colorless liquid with a faint, pleasant odor and is commonly used as a solvent and coupling agent in various industrial applications. Z-MEILE-OH is soluble in water and is often used as a solvent in water-based coatings, dyes, inks, and cleaning products. It is also used as a stabilizer in hydraulic fluids and as a component in some pharmaceutical and cosmetic products. Additionally, it is used as a solvent in the manufacturing of chemical intermediates and as a processing aid in the production of microelectronic and semiconductor devices. However, exposure to Z-MEILE-OH can cause irritation to the respiratory system, skin, and eyes, and it may have harmful effects if ingested or inhaled, so proper safety precautions and handling procedures are necessary when using this chemical.

Upstream product

• 100-52-7 benzaldehyde 
• 73-32-5 L-isoleucine 
• 658691-27-1 C₁₃H₁₇NO₂ 
• 50-00-0 formaldehyd 
• 1859-49-0 (2S,3S)-2-(benzylamino)-3-methylpentanoic acid 

Downstream Products

• 870640-63-4 (2S,3S)-2-(benzyl(methyl)amino)-3-methylpentanal 
• 870640-61-2 (2S,3S)-N-benzyl-1,1-dimethoxy-N,3-dimethylpentan-2-amine 
• 870640-64-5 tert-butyl (3R,4S,5S)-4-[benzyl(methyl)amino]-3-methoxy-5-methyl heptanoate 
• 120205-52-9 tert-butyl (3R,4S,5S)-4-[(2S)-2-[[(benzyloxy)carbonyl]amino]-N,3-dimethylbutanamido]-3-methoxy-5-methylheptanoate 
• 120205-48-3 tert-Butyl (3R,4S,5S)-3-methoxy-4-(N-methylamino)-5-methylheptanoate hydrochloride 
• 669074-47-9 methyl (S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-amino-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanoate 
• 1438852-21-1 methyl (S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanoate 
• 870640-62-3 (2S,3 S)-2-[benzyl(methyl)amino]-3-methylpentan-1-ol 

Relevant articles and documents

CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER

The present invention relates to an antibody-drug-conjugate or pharmaceutical composition comprising the same. From one aspect, the invention relates to an antibody-drug-conjugate (ADC) comprising an antibody consisting of the Trastuzumab or a biosimilar thereof, said antibody being conjugated to at least one drug consisting of a monomethyl auristatin F derivative. The invention also comprises method of treatment of cancer comprising administering to the subject an effective amount of said antibody-drug-conjugate or composition comprising the same.

IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER

The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug- conjugate for the treatment of cancer.

DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS

The present invention concerns a compound of following formula (I) where: - R1 is H or OH, - R2 is a (C1-C6)alkyl, COOH, COO-((C1-C6)alkyl) or thiazolyl group, - R3 is H or a (C1-C6)alkyl group, and - R4 is: - an aryl-(C1-C8)alkyl group substituted by one or more groups chosen from among OH and NR9R10 groups, or - a heterocycle-(C1-C8)alkyl group optionally substituted by one or more groups chosen from among (C1-C6)alkyl, OH and NR12R13 groups, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and its uses in particular for the treatment of cancer, pharmaceutical compositions containing the same and the preparation methods thereof.